Table 3.
Incidence of clinical outcomes across Ramadan.
| Cohort |
Ramadan cohort |
Native Dutch cohort |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Observation period | −2 month | −1 month | Ramadan | +1 month | +2 month | -2 month | -1 month | Ramadan | +1 month | +2 month |
| No. at risk | 3835 | 3813 | 3800 | 3779 | 3760 | 139,207 | 138,079 | 136,940 | 135,785 | 134,651 |
| Major/clinically relevant bleeding | ||||||||||
| No. of events | <10a | <10a | 10 | <10a | <10a | 273 | 266 | 235 | 264 | 235 |
| IR (95% CI), per 100 PYs | Maskeda | Maskeda | 3.22 (1.54-5.92) | Maskeda | Maskeda | 2.40 (2.12-2.70) | 2.36 (2.08-2.66) | 2.10 (1.84-2.39) | 2.38 (2.10-2.68) | 2.13 (1.87-2.43) |
| 30-d cumulative incidence, per 1000 (95% CI) | Maskeda | Maskeda | 2.63 (1.37-4.74) | Maskeda | Maskeda | 1.96 (1.74-2.21) | 1.93 (1.71-2.17) | 1.72 (1.51-1.95) | 1.94 (1.72-2.19) | 1.75 (1.53-1.98) |
| Ischemic stroke/TIA/myocardial infarction/arterial thromboembolism | ||||||||||
| No. of events | 12 | 11 | <10a | <10a | 12 | 324 | 337 | 338 | 299 | 284 |
| IR (95% CI), per 100 PYs | 3.82 (1.98-6.68) | 3.52 (1.76-6.31) | Maskeda | Maskeda | 3.90 (2.02-6.82) | 2.85 (2.55-3.17) | 2.99 (2.68-3.32) | 3.02 (2.71-3.36) | 2.69 (2.40-3.02) | 2.58 (2.29-2.90) |
| 30-d cumulative incidence, per 1000 (95% CI) | 3.13 (1.73-5.36) | 2.88 (1.55-5.06) | Maskeda | Maskeda | 3.19 (1.76-5.47) | 2.33 (2.09-2.59) | 2.44 (2.19-2.71) | 2.47 (2.22-2.74) | 2.20 (1.96-2.46) | 2.11 (1.88-2.37) |
| Composite of bleeding, venous and arterial thromboembolism | ||||||||||
| No. of events | 19 | 14 | 20 | 14 | 14 | 621 | 624 | 597 | 591 | 553 |
| IR (95% CI), per 100 PYs | 6.06 (3.65-9.46) | 4.49 (2.45-7.53) | 6.44 (3.93-9.94) | 4.53 (2.47-7.60) | 4.56 (2.49-7.64) | 5.46 (5.04-5.91) | 5.53 (5.11-5.99) | 5.34 (4.92-5.78) | 5.33 (4.91-5.78) | 5.03 (4.62-5.47) |
| 30-d cumulative incidence per 1000 (95%CI) | 4.95 (3.10-7.62) | 3.67 (2.12-6.05) | 5.26 (3.34-8.01) | 3.70 (2.14-6.10) | 3.72 (2.15-6.13) | 4.46 (4.12-4.82) | 4.52 (4.18-4.88) | 4.36 (4.02-4.72) | 4.35 (4.01-4.71) | 4.11 (3.78-4.46) |
| All-cause mortality | ||||||||||
| No. of events | 22 | 13 | 21 | 19 | 26 | 1,128 | 1,139 | 1,155 | 1,134 | 1,117 |
| IR (95% CI), per 100 PYs | 7.00 (4.39-10.60) | 4.16 (2.21-7.11) | 6.75 (4.18-10.31) | 6.13 (3.69-9.58) | 8.45 (5.52-12.38) | 9.90 (9.33-10.50) | 10.08 (9.51-10.69) | 10.31 (9.72-10.92) | 10.21 (9.62-10.82) | 10.14 (9.56-10.75) |
| 30-d cumulative incidence, per 1000 (95%CI) | 0.57 (0.33-0.81) | 0.34 (0.16-0.53) | 0.55 (0.32-0.79) | 0.50 (0.28-0.73) | 0.69 (0.43-0.96) | 0.81 (0.76-0.86) | 0.82 (0.78-0.87) | 0.84 (0.79-0.89) | 0.84 (0.79-0.88) | 0.83 (0.78-0.88) |
IR, incidence rate; PYs, person-years; TIA, transient ischemic attack.
a
Cells containing <10 individuals are masked according to Statistics Netherlands’ privacy policy. To prevent recalculation of cells <10, sometimes corresponding cells are additionally masked.